LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics Statistics
Share Statistics
LAVA Therapeutics has 26.29M shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 26.29M |
| Shares Change (YoY) | 0.01% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 24.11% |
| Shares Floating | 13.02M |
| Failed to Deliver (FTD) Shares | 1.01K |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 26.44K, so 0.1% of the outstanding shares have been sold short.
| Short Interest | 26.44K |
| Short % of Shares Out | 0.1% |
| Short % of Float | 0.19% |
| Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -0.69. LAVA Therapeutics's PEG ratio is -0.04.
| PE Ratio | -1.01 |
| Forward PE | -0.69 |
| PS Ratio | 6.24 |
| Forward PS | 1.4 |
| PB Ratio | 0.83 |
| P/FCF Ratio | -1.06 |
| PEG Ratio | -0.04 |
Enterprise Valuation
LAVA Therapeutics N.V. has an Enterprise Value (EV) of 4.32M.
| EV / Earnings | -0.1 |
| EV / Sales | 0.64 |
| EV / EBITDA | -0.11 |
| EV / EBIT | -0.1 |
| EV / FCF | -0.11 |
Financial Position
The company has a current ratio of 6.62, with a Debt / Equity ratio of 0.12.
| Current Ratio | 6.62 |
| Quick Ratio | 6.62 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.98 |
| Cash Flow / Debt | -6.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.82% and return on capital (ROIC) is -75.74%.
| Return on Equity (ROE) | -0.82% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -75.74% |
| Revenue Per Employee | $182,945.95 |
| Profits Per Employee | $-1,134,432.43 |
| Employee Count | 37 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 279K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -51.66% in the last 52 weeks. The beta is 0.47, so LAVA Therapeutics's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -51.66% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.61 |
| Relative Strength Index (RSI) | 65.84 |
| Average Volume (20 Days) | 469.77K |
Income Statement
In the last 12 months, LAVA Therapeutics had revenue of 6.77M and earned -41.97M in profits. Earnings per share was -1.57.
| Revenue | 6.77M |
| Gross Profit | 3.29M |
| Operating Income | -43.25M |
| Net Income | -41.97M |
| EBITDA | -40.42M |
| EBIT | -43.25M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
The company has 44.23M in cash and 6.31M in debt, giving a net cash position of 37.92M.
| Cash & Cash Equivalents | 44.23M |
| Total Debt | 6.31M |
| Net Cash | 37.92M |
| Retained Earnings | -148.07M |
| Total Assets | 83.36M |
| Working Capital | 66.34M |
Cash Flow
In the last 12 months, operating cash flow was -38.97M and capital expenditures -730K, giving a free cash flow of -39.7M.
| Operating Cash Flow | -38.97M |
| Capital Expenditures | -730K |
| Free Cash Flow | -39.7M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 48.56%, with operating and profit margins of -638.99% and -620.09%.
| Gross Margin | 48.56% |
| Operating Margin | -638.99% |
| Pretax Margin | -615.97% |
| Profit Margin | -620.09% |
| EBITDA Margin | -597.09% |
| EBIT Margin | -638.99% |
| FCF Margin | -586.53% |
Dividends & Yields
LVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -119.85% |
| FCF Yield | -115.27% |
Analyst Forecast
The average price target for LVTX is $2, which is 52.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 52.7% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -2.49 |
| Piotroski F-Score | 2 |